In conclusion, upfront cranial SRS combined with EGFR-TKIs may improve intracranial-free survival and progression-free survival outcomes compared with upfront TKIs for EGFR-mutated NSCLC patients with limited synchronous BMs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.